Why the study?
Does perhexiline improve cardiac energetic impairment, diastolic dysfunction, and exercise capacity in patients with symptomatic hypertrophic cardiomyopathy?
Does perhexiline improve cardiac energetic impairment, diastolic dysfunction, and exercise capacity in patients with symptomatic hypertrophic cardiomyopathy?
Perhexiline improves cardiac energetics, diastolic function, and exercise capacity in symptomatic hypertrophic cardiomyopathy, providing a rationale for metabolic therapies in this condition.
Answers are grounded in this paper and cite their sources.
Supports perhexiline in symptomatic HCM; extends rationale for metabolic therapies in cardiomyopathies.
In symptomatic hypertrophic cardiomyopathy, perhexiline, a modulator of substrate metabolism, ameliorates cardiac energetic impairment, corrects diastolic dysfunction, and increases exercise capacity. This study supports the hypothesis that energy deficiency contributes to the pathophysiology and provides a rationale for further consideration of metabolic therapies in hypertrophic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Abozguia et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: